Skip to main content

Table 2 Toxicity profile

From: Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial

  Grades 1–2 Grade 3 Grade 4 Grade 5
Non-hematological adverse events
 Fatigue 15 (24.2%) 0 0 0
 Neuropathy 23 (37.1%) 0 0 0
 Anorexia 22 (35.5%) 0 0 0
 Alopecia 41 (66.1%) 0 0 0
 Diarrhea 6 (9.7%) 0 0 0
 Epistaxis 5 (8.1%) 0 0 0
 Vomiting 5 (8.1%) 1 (1.6%) 0 0
 Peripheral edema 6 (9.7%) 1 (1.6%) 0 0
 Hypertension 8 (12.9%) 5 (8.1%) 0 0
 Constipation 5 (8.1%) 0 0 0
 Dyspnea 7 (11.3%) 0 0 0
 Weight decreased 5 (8.1%) 0 0 0
 Ascites 3 (4.8%) 0 0 0
 Myalgia 6 (9.7%) 0 0 0
 Nausea 9 (14.5%) 0 0 0
 Rash 8 (12.9%) 1 (1.6%) 0 0
 Mucositis 11 (17.7%) 0 0 0
 Back pain 4 (6.5%) 0 0 0
 Cough 4 (6.5%) 0 0 0
Hematologic adverse events
 Neuropenia 13 (21.0%) 16 (25.8%) 5 (8.1%) 0
 Febrile neutropenia 0 1 (1.6%) 0 0
 Anemia 18 (29.0%) 2 (3.2%) 0 0
 Thrombocytopenia 2 (3.2%) 0 0 0